TROPION-Breast02

FDA Approves Datroway as First‑Line Option for Immunotherapy‑Ineligible Triple‑Negative Breast Cancer

Regulators cleared the TROP2‑targeting antibody‑drug conjugate after Phase III data showed a meaningful survival benefit versus chemotherapy, creating a new first‑line choice for patients who cannot receive PD‑1/PD‑L1 therapy.